Evidence map›Paper›PMID 42144462›Full record

ArticleEuropean spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society2026

Endovascular-microsurgical treatment of hypervascular spinal tumors: influence of cervical, thoracic, and lumbar vascular anatomy on embolization decisions and primary clinical outcomes (25-case series).

Dmitry E Zakondyrin, Eduard E Rostorguev, Amirhossein Hosseini, Saidi S Gaibov, Konstantin S Sergeev, Dmiriy Khrupa, Myasnik A Arabhanyan, Vladimir Malchevskiy

Abstract read
PubMed Publisher
In one paragraph

Article in European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Dmitry E ZakondyrinSechenov First Moscow State Medical University, Moscow, Russian Federation. russiandoctor@mail.ru.
Eduard E RostorguevNational Medical Research Center for Oncology, Rostov-on-Don, Russian Federation.
Amirhossein HosseiniSechenov First Moscow State Medical University, Moscow, Russian Federation.
Saidi S GaibovTyumen State Medical University, Tyumen, Russian Federation.
Konstantin S SergeevTyumen State Medical University, Tyumen, Russian Federation.
Dmiriy KhrupaRegional Clinical Hospital №2, Tyumen, Russian Federation.
Myasnik A ArabhanyanRegional Clinical Hospital №2, Tyumen, Russian Federation.
Vladimir MalchevskiyTyumen Scientific Center Siberian Branch, Tyumen, Russian Federation.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo assess whether preoperative spinal angiography with endovascular embolization followed by microsurgical resection is technically feasible and safe for hypervascular spinal tumors, and to examine how cervical, thoracic, and lumbar vascular anatomy influences feasibility.

methodsWe retrospectively reviewed 25 patients treated from 2017 to 2025 at two centers (14 men, 11 women; mean age 53 years) with hypervascular tumors involving the cervical (n = 3), thoracic (n = 15), lumbar and sacral (n = 7) spine. All underwent preoperative angiography (DSA)-embolization (within the same procedure if technically possible). We recorded whether embolization could be safely performed and any embolization-related complications; we also graded angiographic devascularization (devascularization grade, DG) and operative estimated blood loss (EBL). Selective or super-selective embolization was performed when arterial anatomy allowed safe catheterization, and surgery followed within 24-48 h.

resultsEmbolization was feasible in 23/25 patients (92%): thoracic 15/15 (100%), lumbar 6/6 (100%), sacral 1/1 (100%), and cervical 1/3 (33%). Two cervical RCC (renal cell carcinoma) metastases were not embolized because multiple short feeders shared trunks with radiculomedullary (spinal cord-supplying) arteries, precluding safe super-selective access. Among embolized cases, super-selective feeder occlusion was performed in 5/23 (21.7%) and segmental-vessel embolization in 18/23 (78.3%) using precipitating hydrophobic injectable liquid (PHIL), coils, and n-butyl cyanoacrylate (NBCA). High-grade devascularization (DG2-3) was achieved in all embolized cases, and completion angiography showed no or minimal residual tumor blush. There were no permanent embolization-related neurological deficits (0/23); one transient ischemic event occurred (1/23, 4.3%; vertebrobasilar ischemia in a C2 aneurysmal bone cyst) with full recovery. Mean estimated blood loss was 650 mL (median 600; range 400-800 mL. Differences in mean EBL between subsets of RCC and non-RCC tumors were statistically unsignificant, Correlations between DG and EBL was not identified.

conclusionA coordinated endovascular-surgical pathway achieved high embolization feasibility with no permanent embolization-related neurological complications, and no postoperative neurological deterioration in this cohort. Feasibility limitations were concentrated in the cervical spine, where short, shared feeders involving spinal cord-supplying arteries can preclude safe embolization. Limitations include retrospective design, small cohort with few cervical cases, and heterogeneous tumors/embolic agents; prospective studies with standardized devascularization and functional outcome metrics are warranted.

Indexed as

AngiographyNeurosurgical proceduresSpinal neoplasmsTherapeutic embolizationVertebral neoplasms

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.